Key Drivers
- High EBITDA margins
- Negative free cashflow
- Material leverage
AIAI Summary
Sabra's deliberate pivot to managed SHOP can drive meaningful AFFO and NAV upside if management proves SHOP stabilization and converts accrual earnings into positive free cash flow within 12–18 months, but the investment hinges on that execution—monitor near-term metrics (AFFO-to-cash conversion, FCF, dividend coverage, and SHOP same-store cash NOI) because continued negative FCF, a ~188% payout ratio, and ~5x net leverage present the clearest paths to a sharp re‑rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High EBITDA margins
- •Negative free cashflow
- •Material leverage
SBRA posts strong reported profitability and high EBITDA margins but suffers negative free cash flow, heavy leverage, poor capital efficiency, and an unsustainable dividend.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Tight range
- •Mild downside risk
Price sits below the last month SMA (~$20.48) at $19.59, trading in a tight $19.6–$20.9 range with mild short-term downside pressure but potential mean-reversion if buyers push above $20.5–$20.6.
Failed attempts to sustain moves above $20.8 and a close below the last month
Sentiment & News
Key News Insights:
- •4.9%–5.4% FFO growth
- •5.84% dividend yield
- •Mixed institutional flows
Sabra Health Care REIT shows steady guidance, active investor engagement, and mixed institutional positioning amid a moderate-buy analyst consensus and planned 2026 investments.
The combination of clear financial guidance, maintained dividend yield, and management outreach should support investor confidence, though divergent institutional trades leave near-term share direction uncertain
Similar Companies in Real Estate
Other companies in the same sector with AI ratings